TOPIC
 / company

BeOne

BeOne
The latest news and top stories on BeOne Medicines. Hong Kong-listed BeOne Medicines, formerly BeiGene, specialises in developing and selling innovative oncology products. Headquartered in Beijing China with global operations, they primarily serve cancer patients worldwide, addressing unmet medical needs. Notable for its rapid growth and pioneering advancements in immuno-oncology, the company's key products include the blood cancer drug zanubrutinib (Brukinsa) and the oncology drug tislelizumab (Tevimbra). BeOne Medicines anticipates significant net profit, reflecting its focus on transforming cancer treatment through cutting-edge research and global expansion.
China’s private sector

BeOne Medicines names R&D chief Wang Lai as president amid global expansion

BeOne generated global revenue of about US$3.8 billion last year, driven by its flagship products Brukinsa and Tevimbra.

China’s pharmaceutical industry transforms into a global innovation powerhouse

Chinese drug start-ups poised for 2025 profits, in industry milestone

Innovent likely to post a first-half net profit of US$36.4 million, and BeOne’s first-half net profit is expected to come in at US$42 million.

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement